Aligos Therapeutics, Inc. (ALGS) NASDAQ

5.25

-0.1(-1.87%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Lawrence Blatt	Chief Executive Officer, President & Chairman of the Board	1.04M	1962
Julian A. Symons DPHIL	Executive Vice President & Chief Scientific Officer	693,977	1962
Lesley Ann Calhoun	Executive Vice President, Chief Financial Officer & Chief Operating Officer	704,760	1966
Nikhil Aneja	Principal Accounting Officer	0	1977
Kieron Wesson	Vice President & Head of Chemistry Manufacturing Controls	0	N/A
Tse-I Lin	Senior Vice President of Early Compound Development & Belgian Site Head	0	N/A
Laura Kavanaugh	Vice President & Head of Legal	0	N/A
Ramon Polo	Senior VP & Head of Global Regulatory Affairs	0	N/A
Sushmita Chanda DABT	Executive Vice President & Chief Development Officer	0	1967
Kristina Engeseth	Senior Vice President and Head of People & Culture	0	N/A
David Smith	Executive Vice President & Head of Chemical Operations	0	N/A
James Hassard	Executive VP & Chief Commercial Officer	0	1967

Name

Title

Pay

Year Born

Lawrence Blatt

Chief Executive Officer, President & Chairman of the Board

1.04M

1962

Julian A. Symons DPHIL

Executive Vice President & Chief Scientific Officer

693,977

1962

Lesley Ann Calhoun

Executive Vice President, Chief Financial Officer & Chief Operating Officer

704,760

1966

Nikhil Aneja

Principal Accounting Officer

1977

Kieron Wesson

Vice President & Head of Chemistry Manufacturing Controls

N/A

Tse-I Lin

Senior Vice President of Early Compound Development & Belgian Site Head

N/A

Laura Kavanaugh

Vice President & Head of Legal

N/A

Ramon Polo

Senior VP & Head of Global Regulatory Affairs

N/A

Sushmita Chanda DABT

Executive Vice President & Chief Development Officer

1967

Kristina Engeseth

Senior Vice President and Head of People & Culture

N/A

David Smith

Executive Vice President & Head of Chemical Operations

N/A

James Hassard

Executive VP & Chief Commercial Officer

1967

Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.